Adynamic bone disease: clinical and therapeutic implications

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 4, 2009, Pages 303-307

  Frazão, João M ^a,b   Martins, Patrícia ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Adynamic bone disease; chronic kidney disease; hemodialysis; vascular calcification

Indexed keywords

ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; BIOLOGICAL MARKER; CALCIUM; CALCIUM CARBONATE; LANTHANUM CARBONATE; PARATHYROID HORMONE; SEVELAMER; VITAMIN D;

ADYNAMIC BONE DISEASE; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CHRONIC KIDNEY DISEASE; DRUG MEGADOSE; HEMODIALYSIS PATIENT; HUMAN; LOW DRUG DOSE; MORTALITY; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; PARATHYROID FUNCTION; PRIORITY JOURNAL; REVIEW;

ANIMALS; BONE DISEASES; BONE REMODELING; CALCINOSIS; CALCIUM; CHRONIC DISEASE; CORONARY ARTERY DISEASE; HUMANS; KIDNEY DISEASES; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 67849096870     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32832c4df0     Document Type: Review

References (39)

1. Block G, Hulbert-Shearon T, Levin N, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-617.
2. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208-2218.
3. Blacher J, Gué rin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938-942.
4. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953.
5. Sherrard DJ, Out S, Maloney NA. Uremic osteodystrophy, classification, cause, and treatment. In: Frame B, Potts JRJ, editors. Clinical disorders of bone and mineral metabolism. Amesterdam: Excerpta Medica; 1983. pp. 254-259.
6. Malluche HH, Faugere MC. Atlas of mineralized bone histology. Basel: Karger; 1986.
7. Spasovski GB. Bone biopsy as a diagnostic tool in the assessment of renal osteosdystrophy. Int J Artif Organs 2004; 27:918-923.
8. Cannata-Andia JB. Hypokinetic azotemic osteodystrophy. Kidney Int 1998; 54:1000-1016.
9. Brandenburg VM, Floege J. Adynamic bone disease: bone and beyond. NDT Plus 2008; 3:135-147. This is an excellent and very comprehensive review of adynamic bone disease.
10. Nebeker HG, Coburn JW. Aluminum and renal osteodystrophy. Annu Rev Med 1986; 37:79-95.
11. Savory J, Bertholf RL, Wills MR. Aluminum toxicity in chronic renal insufficiency. Clin Endocrinol Metab 1985; 14:681-702.
12. Barreto FC, Barreto DV, Moyses RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73:771-777. This interesting study tested the effectiveness of the K/DOQI-suggested iPTH target range indialysispatients with CKD stage 5 forpreventing bone-remodeling disorders in hemodialysis patients. The bone biopsies from patients with iPTH levels within the recommended K/DOQI guidelines range showed a high incidence of low-turnover bone disease. The data suggest that other biochemical markers may be required to accurately measure bone-remodeling status in hemodialysis patients.
13. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant 2004; 19 (Suppl 1):i9-i13.
14. Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 2003; 18:1159-1166.
15. Ferreira A, Frazão JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19:405-412. This randomized, open-label study, conducted in 119 hemodialysis patients over 54 weeks compared the effects of sevelamer hydrochloride and calcium carbonate on bone. Biopsy-proven adynamic bone disease was the most frequent bone abnormality at baseline (59%). Sevelamer resulted in no statistically significant changes in bone turnover or mineralization compared with calcium carbonate, but the bone formation rate increased and trabecular architecture improved with sevelamer treatment.
16. Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006; 36 (Suppl 2):13-22.
17. Goodman WG. Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis. Semin Dial 2007; 20:1-4.
18. Goodman WG. The evolution of assays for parathyroid hormone. Semin Dial 2005; 18:296-301.
19. Monier-Faugere MC, Geng Z, Mawad H, et al. Improved assessment of bone turnover by PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60:1460-1468.
20. Haas M, Leko-Mohr Z, Roschger P, et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002; 39:580-586.
21. Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodelling in uremic patients. Kidney Int 1999; 55:2141-2156.
22. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15:1943-1951.
23. Danese MD, Kim J, Doan QV, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47:149-156.
24. London GM, Gué rin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephol Dial Transplant 2003; 18:1731-1740.
25. Adragão T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1480-1488.
26. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39:695-701.
27. Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46:855-861.
28. Asci G, Ozkahya M, Duman S, et al. The link between cardiovascular and bone disease in hemodialysis patients. Nephrol Dial Transplant 2007; 22(Suppl 6): vi 217 (MO014).
29. London GM, Marchais SJ, Gé rin AP, et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19:1827-1835. Using bone histomorphometry and pulse wave velocity in 66 dialysis patients, there was a positive relationship between calcium load, bone activity and aortic stiffness. These positive associations were stronger in patients with adynamic bone disease.
30. Barreto DV, Barreto FC, Carvalho AB, et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 52:1139-1150. This prospective study evaluated the association between bone remodeling disorders and progression of coronary artery calcification in 64 hemodialysis patients. Bone-related laboratory parameters and bone histomorphometric characteristics were assessed at baseline and after 1 year of follow-up. Low-turnover bone disease correlated with coronary artery calcification scores assessed by coronary multislice tomography and its progression.
31. D"Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63 (Suppl):S73-S78.
32. Adragao T, Herberth J, Monier-Faugere MC, et al. Low bone volume: a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:450-455.
33. Fugimori A, Yorifuji M, Sakai M, et al. Low-calcium dialysate improves mineral metabolism in hemodialysis patients. Clin Nephrol 2007; 67:20-24.
34. Haris A, Sherrard DJ, Hercz G. Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 2006; 70:931-937.
35. Igarashi P, Aronson PS. Late-breaking clinical trials at renal week 2008. Clin J Am Soc Nephrol 2008; 3:RB01-RB04. One of the abstracts in this special session at the Renal Week 2008 presented a study conducted in a large population of prevalent dialysis patients with a follow-up of 24 months. In this bone biopsy study, the authors showed that lowering dialysate Ca level induced an improvement in bone turnover, bone formation and reduced coronary artery calcifications progression evaluated by multislice CT.
36. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46:1160-1166.
37. Kuizon BD, Goodman WG, Juppner H, et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998; 53:205-211.
38. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16:1115-1125.
39. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70:771-780.